or Try an Advanced Search...

    Dyslipidemia Stocks List

    Symbol Grade Name % Change
    ABT A Abbott Laboratories -0.68
    ARGX B argenx SE 1.17
    MDGL C Madrigal Pharmaceuticals, Inc. 3.52
    VKTX F Viking Therapeutics, Inc. 4.89
    IONS F Ionis Pharmaceuticals, Inc. 0.06
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia

    Related ETFs - A few ETFs which own one or more of the above listed Dyslipidemia stocks.

    Symbol Grade Name Weight
    IHI A iShares U.S. Medical Devices ETF 16.82
    MNTL F Tema Neuroscience and Mental Health ETF 7.14
    GDOC D Goldman Sachs Future Health Care Equity ETF 6.73
    BMED D BlackRock Future Health ETF 6.1
    XBI D SPDR S&P Biotech ETF 5.88
    View all Dyslipidemia ETFs...
    Compare ETFs
    Compare BMED to XBI Compare GDOC to XBI Compare IHI to BMED

        Dyslipidemia Stocks Recent News

        Date Stock Title
        Nov 18 ABT Inside a $400 billion bet on the brain-computer interface revolution
        Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
        Nov 18 ARGX Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
        Nov 18 VKTX 3 Things You Need to Know if You Buy Viking Therapeutics Today
        Nov 18 MDGL The first MASH drug could open the door for others — including GLP-1s
        Nov 17 VKTX Is It Too Late to Buy Viking Therapeutics Stock?
        Nov 17 ABT First mpox case linked to African outbreak reported in U.S.
        Nov 17 ABT Abbott Laboratories (ABT): A Magnificent Dividend Growth Stock to Buy Now
        Nov 16 VKTX Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
        Nov 16 ABT Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
        Nov 15 MDGL Madrigal Pharmaceuticals gains amid takeover speculation
        Nov 15 VKTX Market Whales and Their Recent Bets on VKTX Options
        Nov 15 VKTX Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
        Nov 15 MDGL John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
        Nov 14 MDGL Paulson & Co. exits AngloGold Ashanti, boosts Madrigal Pharma among Q3 moves
        Nov 14 ARGX (ARGX) - Analyzing argenx's Short Interest
        Nov 14 ABT 3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
        Nov 13 VKTX Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
        Nov 13 ABT US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024
        Nov 13 VKTX Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Lipid Cancer Diabetes Thyroid Alcohol Biopharmaceutical Cholesterol Hypercholesterolemia Inflammation Medication Medicine Metabolic Disease Obesity Steatohepatitis Acromegaly Acute Myeloid Leukemia Alport Syndrome Amyloid Amyloidosis Anemia
        Dyslipidemia

        Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

        More about Dyslipidemia
        Browse All Tags